CN1346273A - 使用性激素来获得可用于治疗不合需要的子宫出血的鼻腔药物组合物 - Google Patents
使用性激素来获得可用于治疗不合需要的子宫出血的鼻腔药物组合物 Download PDFInfo
- Publication number
- CN1346273A CN1346273A CN00804471A CN00804471A CN1346273A CN 1346273 A CN1346273 A CN 1346273A CN 00804471 A CN00804471 A CN 00804471A CN 00804471 A CN00804471 A CN 00804471A CN 1346273 A CN1346273 A CN 1346273A
- Authority
- CN
- China
- Prior art keywords
- estradiol
- purposes
- pharmaceutical composition
- cyclodextrin
- progestogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 206010046788 Uterine haemorrhage Diseases 0.000 title abstract 2
- 239000003163 gonadal steroid hormone Substances 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title description 14
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 23
- 229960005309 estradiol Drugs 0.000 claims description 20
- 229930182833 estradiol Natural products 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 239000000583 progesterone congener Substances 0.000 claims description 11
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 11
- 229920000858 Cyclodextrin Polymers 0.000 claims description 10
- 206010027514 Metrorrhagia Diseases 0.000 claims description 9
- 210000003928 nasal cavity Anatomy 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 229940011871 estrogen Drugs 0.000 claims description 3
- 239000000262 estrogen Substances 0.000 claims description 3
- 229940053934 norethindrone Drugs 0.000 claims description 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 3
- -1 19-nortestosterone chemical compounds Chemical class 0.000 claims description 2
- 229960004719 nandrolone Drugs 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000001186 cumulative effect Effects 0.000 claims 1
- 239000000745 gonadal hormone Substances 0.000 description 9
- 208000032843 Hemorrhage Diseases 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 206010030247 Oestrogen deficiency Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 229960004190 nomegestrol acetate Drugs 0.000 description 2
- IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- 150000000307 17β-estradiols Chemical class 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 229960001853 demegestone Drugs 0.000 description 1
- JWAHBTQSSMYISL-MHTWAQMVSA-N demegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 JWAHBTQSSMYISL-MHTWAQMVSA-N 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960004913 dydrogesterone Drugs 0.000 description 1
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229940012028 ethynodiol diacetate Drugs 0.000 description 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 229960005352 gestodene Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 229960000606 medrogestone Drugs 0.000 description 1
- HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229960000417 norgestimate Drugs 0.000 description 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001584 promegestone Drugs 0.000 description 1
- QFFCYTLOTYIJMR-XMGTWHOFSA-N promegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)CC)(C)[C@@]1(C)CC2 QFFCYTLOTYIJMR-XMGTWHOFSA-N 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9904022A FR2791572A1 (fr) | 1999-03-31 | 1999-03-31 | Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables |
| FR99/04022 | 1999-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1346273A true CN1346273A (zh) | 2002-04-24 |
Family
ID=9543854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00804471A Pending CN1346273A (zh) | 1999-03-31 | 2000-03-30 | 使用性激素来获得可用于治疗不合需要的子宫出血的鼻腔药物组合物 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1143978A2 (fr) |
| JP (1) | JP2002541076A (fr) |
| KR (1) | KR20010102464A (fr) |
| CN (1) | CN1346273A (fr) |
| AU (1) | AU3662300A (fr) |
| BR (1) | BR0008577A (fr) |
| CA (1) | CA2361885A1 (fr) |
| EA (1) | EA200100801A1 (fr) |
| FR (1) | FR2791572A1 (fr) |
| HK (1) | HK1044486A1 (fr) |
| HU (1) | HUP0200244A3 (fr) |
| NO (1) | NO20014022D0 (fr) |
| NZ (1) | NZ513672A (fr) |
| PL (1) | PL356767A1 (fr) |
| WO (1) | WO2000059447A2 (fr) |
| ZA (1) | ZA200106689B (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4383993A (en) * | 1980-05-30 | 1983-05-17 | University Of Kentucky Research Foundation | Nasal dosage forms containing natural female sex hormones |
| NL8801670A (nl) * | 1988-07-01 | 1990-02-01 | Walter Adrianus Josephus Johan | Farmaceutisch preparaat. |
| US5922699A (en) * | 1996-06-07 | 1999-07-13 | Pherin Corporation | 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function |
| WO1998003207A1 (fr) * | 1996-07-23 | 1998-01-29 | Pherin Pharmaceuticals, Inc. | Steroides utilises en qualite de stimulateurs neurochimiques de l'organe vomero-nasal et permettant de soulager les symptomes premenstruel et de l'anxiete |
-
1999
- 1999-03-31 FR FR9904022A patent/FR2791572A1/fr not_active Withdrawn
-
2000
- 2000-03-30 NZ NZ513672A patent/NZ513672A/xx not_active Application Discontinuation
- 2000-03-30 BR BR0008577-4A patent/BR0008577A/pt not_active IP Right Cessation
- 2000-03-30 CA CA002361885A patent/CA2361885A1/fr not_active Abandoned
- 2000-03-30 KR KR1020017011124A patent/KR20010102464A/ko not_active Application Discontinuation
- 2000-03-30 WO PCT/FR2000/000790 patent/WO2000059447A2/fr not_active Application Discontinuation
- 2000-03-30 EA EA200100801A patent/EA200100801A1/ru unknown
- 2000-03-30 CN CN00804471A patent/CN1346273A/zh active Pending
- 2000-03-30 JP JP2000609012A patent/JP2002541076A/ja active Pending
- 2000-03-30 EP EP00915247A patent/EP1143978A2/fr not_active Withdrawn
- 2000-03-30 HU HU0200244A patent/HUP0200244A3/hu unknown
- 2000-03-30 PL PL00356767A patent/PL356767A1/xx not_active Application Discontinuation
- 2000-03-30 AU AU36623/00A patent/AU3662300A/en not_active Abandoned
-
2001
- 2001-08-14 ZA ZA200106689A patent/ZA200106689B/en unknown
- 2001-08-17 NO NO20014022A patent/NO20014022D0/no not_active Application Discontinuation
-
2002
- 2002-08-23 HK HK02106208.3A patent/HK1044486A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL356767A1 (en) | 2004-07-12 |
| AU3662300A (en) | 2000-10-23 |
| JP2002541076A (ja) | 2002-12-03 |
| WO2000059447A3 (fr) | 2001-04-26 |
| EP1143978A2 (fr) | 2001-10-17 |
| NZ513672A (en) | 2001-09-28 |
| HUP0200244A3 (en) | 2003-05-28 |
| WO2000059447A2 (fr) | 2000-10-12 |
| BR0008577A (pt) | 2002-10-01 |
| NO20014022L (no) | 2001-08-17 |
| ZA200106689B (en) | 2002-11-14 |
| HUP0200244A2 (hu) | 2002-07-29 |
| HK1044486A1 (zh) | 2002-10-25 |
| NO20014022D0 (no) | 2001-08-17 |
| EA200100801A1 (ru) | 2002-04-25 |
| KR20010102464A (ko) | 2001-11-15 |
| FR2791572A1 (fr) | 2000-10-06 |
| CA2361885A1 (fr) | 2000-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8076319B2 (en) | Treatment of conditions relating to hormone deficiencies by administration of progestins | |
| AU2002309919A1 (en) | Treatment of conditions relating to hormone deficiencies by administration of progestins | |
| JPH09502194A (ja) | 少なくとも１種のプロゲストーゲンおよび少なくとも１種のエストロゲンを含む、代替療法用製剤 | |
| HUT74428A (en) | Hormonal pharmaceutical compositions for contraception and treatment of acne | |
| KR101075929B1 (ko) | 아로마타제 억제제, 프로게스틴 및 에스트로겐의 조합물을포함하는 조성물 및 자궁내막증의 치료를 위한 이의 용도 | |
| JP2942560B2 (ja) | エストロゲン欠乏症治療用組成物 | |
| CN1346273A (zh) | 使用性激素来获得可用于治疗不合需要的子宫出血的鼻腔药物组合物 | |
| CA2248841C (fr) | Combinaison sequentielle oestrogene/antagoniste de la progesterone s'utilisant en therapie hormonale de substitution | |
| Mansour | Use of the new progestogens in contraception and gynaecology | |
| WO2004112797A1 (fr) | Hormonotherapie substitutive et traitement de la depression comportant l'administration d'un dienogest | |
| MXPA01008772A (en) | Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding | |
| BG106443A (bg) | Мезопрогестини (прогестерон рецептор модулатори) като компонент на състави за хормонозаместваща терапия | |
| NZ236755A (en) | Composition for alleviating menopausal symptoms comprising melatonin and an estrogen and/or an androgen. | |
| KR20010110807A (ko) | 조합 치료에서의 항프로게스타겐의 용도 | |
| AU2003206424B2 (en) | Sequential estrogen/progesterone antagonist combination for hormone replacement therapy | |
| Moghadam et al. | Advances in menopausal hormonal therapy delivery systems: a comparative review | |
| MXPA98007513A (en) | Sequencial combination of estrogen / antagonist of progesterone for therapy of replacement of hormo | |
| JPH10279483A (ja) | 骨密度増加剤 | |
| EP1522306A1 (fr) | Un produit pharmaceutique pour le traitement hormonal substitutif contenant la tibolone ou un de ses dérivés et l'estradiol ou un de ses dérivés | |
| TH134365B (th) | โดรสไพริโนนสำหรับการรักษาด้วยการแทนที่ฮอร์โมน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1044486 Country of ref document: HK |